Summary
A 39-year-old defense consultant was denied a security clearance under Guideline H (Drug Involvement) due to an extensive history of marijuana use and purchases. The applicant admitted to using marijuana on at least 50 occasions and purchasing it on at least 45 occasions between 2000 and March 2007. These actions raised disqualifying conditions DC 25(a) and DC 25(c).
Despite ceasing marijuana use in March 2007 and expressing an intent to abstain in the future, the judge determined that the applicant's past conduct presented significant security concerns. The judge found that the applicant's year of abstinence was insufficient to mitigate the risks associated with his prolonged drug involvement.
Ultimately, the applicant's assurances of future abstinence were considered untested and inadequate to overcome the security concerns stemming from his admitted history of marijuana use and purchases. The security clearance was therefore denied.
Why the Applicant Was Denied
- The applicant admitted to using marijuana on at least 50 occasions and purchasing it on at least 45 occasions from 2000 to 2007.
- The judge determined that the applicant's extensive history of drug involvement raised significant security concerns that were not mitigated by his year of abstinence.
- The applicant's assurances of future abstinence were deemed untested and insufficient to overcome the risks associated with his past behavior.
Conditions Referenced
- DC 25(a)raisedAny Drug Abuse
- DC 25(c)raisedIllegal Drug Possession
Key Rule Quoted
“A decision to grant or continue an applicant's security clearance may be made only upon a threshold finding that to do so is clearly consistent with the national interest.”
Procedural Posture
- SOR issuedJan 14, 2008
- Answer filedFeb 5, 2008
- Hearing heldApr 29, 2008
- Decision dateAug 11, 2008
Cite For
- Denial Based on Extensive History of Drug Use Under Guideline H
- Insufficient Mitigation of Security Concerns Despite Claims of Abstinence
- Importance of Demonstrating a Longer Period of Abstinence for Mitigating Drug Involvement Risks